title: DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform.
abstract: It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expression assay that is designed to predict which patients are likely to experience long-term (> 2 years) progression-free survival.
authors.affiliation: Hayes, Inc.
authors.forename: Diane
authors.initials: D
authors.lastname: Allingham-Hawkins
authors.forename: Andrew
authors.initials: A
authors.lastname: Lea
authors.forename: Susan
authors.initials: S
authors.lastname: Levine